trichostatin A
Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.
Cross Reference
Introduction
To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with trichostatin A?
trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with trichostatin A
PubChem Associated disorders and diseases
What pathways are associated with trichostatin A
Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with trichostatin A?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with trichostatin A?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with trichostatin A?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with trichostatin A?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with trichostatin A?
Mouse Model
Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).
Xenograft Model
Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).
Cancer Model
Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with trichostatin A
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yang X et al. | Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. | 2001 | Cancer Res. | pmid:11585728 |
| Luo W et al. | Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. | 2010 | Cancer Res. | pmid:20587525 |
| Sasaki Y et al. | p53 negatively regulates the hepatoma growth factor HDGF. | 2011 | Cancer Res. | pmid:22006999 |
| Phan D et al. | Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. | 2004 | Cancer Res. | pmid:15126343 |
| Wang X et al. | Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. | 2009 | Cancer Res. | pmid:19752087 |
| Wei M et al. | BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. | 2005 | Cancer Res. | pmid:16322213 |
| Hatjiharissi E et al. | Proteomic analysis of waldenstrom macroglobulinemia. | 2007 | Cancer Res. | pmid:17440091 |
| Hellebrekers DM et al. | Identification of epigenetically silenced genes in tumor endothelial cells. | 2007 | Cancer Res. | pmid:17483324 |
| James SY et al. | Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. | 2003 | Cancer Res. | pmid:12839938 |
| Fahrner JA et al. | Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. | 2002 | Cancer Res. | pmid:12499261 |
| Terui T et al. | Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. | 2003 | Cancer Res. | pmid:14695212 |
| Shah S et al. | Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. | 2012 | Cancer Res. | pmid:22258452 |
| Lau QC et al. | RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. | 2006 | Cancer Res. | pmid:16818622 |
| Foltz G et al. | Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. | 2006 | Cancer Res. | pmid:16818640 |
| Sharma D et al. | Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. | 2006 | Cancer Res. | pmid:16778215 |
| Shi J et al. | Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. | 2007 | Cancer Res. | pmid:17616702 |
| Su Y et al. | Human RecQL4 helicase plays critical roles in prostate carcinogenesis. | 2010 | Cancer Res. | pmid:21045146 |
| Qi H and Ratnam M | Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. | 2006 | Cancer Res. | pmid:16740727 |
| Ibanez de Caceres I et al. | Identification of novel target genes by an epigenetic reactivation screen of renal cancer. | 2006 | Cancer Res. | pmid:16707423 |
| Imre G et al. | Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. | 2006 | Cancer Res. | pmid:16707469 |
| Singal R et al. | Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. | 2001 | Cancer Res. | pmid:11406558 |
| Maecker HL et al. | p53 promotes selection for Fas-mediated apoptotic resistance. | 2000 | Cancer Res. | pmid:10969818 |
| Badia E et al. | Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. | 2000 | Cancer Res. | pmid:10945620 |
| Blagosklonny MV et al. | Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. | 2005 | Cancer Res. | pmid:16103091 |
| Sirchia SM et al. | Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. | 2002 | Cancer Res. | pmid:11980632 |
| Shin JY et al. | Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. | 2000 | Cancer Res. | pmid:10667572 |
| Kretzner L et al. | Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. | 2011 | Cancer Res. | pmid:21502403 |
| Saunders N et al. | Histone deacetylase inhibitors as potential anti-skin cancer agents. | 1999 | Cancer Res. | pmid:9927053 |
| Ramsey MR et al. | Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. | 2011 | Cancer Res. | pmid:21527555 |
| Medina V et al. | Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. | 1997 | Cancer Res. | pmid:9288776 |
| Harada K et al. | Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. | 2002 | Cancer Res. | pmid:12384554 |
| Wilson AJ et al. | Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. | 2002 | Cancer Res. | pmid:12414619 |
| Ho WC et al. | Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. | 2005 | Cancer Res. | pmid:15899819 |
| Tran T et al. | Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. | 2005 | Cancer Res. | pmid:15899836 |
| Kim MS et al. | Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. | 2003 | Cancer Res. | pmid:14612526 |
| Majid S et al. | Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. | 2010 | Cancer Res. | pmid:20332239 |
| Liu LT et al. | Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. | 2003 | Cancer Res. | pmid:12810630 |
| Allison SJ and Milner J | Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy. | 2003 | Cancer Res. | pmid:14583461 |
| Sowa Y et al. | Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. | 1999 | Cancer Res. | pmid:10485470 |
| Lin YC et al. | Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. | 2008 | Cancer Res. | pmid:18381445 |
| Myzak MC et al. | A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. | 2004 | Cancer Res. | pmid:15313918 |
| Kim TY et al. | Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. | 2006 | Cancer Res. | pmid:16885346 |
| Xiong Y et al. | Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. | 2005 | Cancer Res. | pmid:15805266 |
| Ferrara FF et al. | Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. | 2001 | Cancer Res. | pmid:11196162 |
| Kumakura S et al. | Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. | 2005 | Cancer Res. | pmid:15805278 |
| Zhao S et al. | Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. | 2003 | Cancer Res. | pmid:12750289 |
| Yang X et al. | Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. | 2000 | Cancer Res. | pmid:11156387 |
| Stiehl DP et al. | Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. | 2007 | Cancer Res. | pmid:17332356 |
| Mori T et al. | Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. | 2005 | Cancer Res. | pmid:15753377 |
| Pellicciotta I et al. | Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. | 2008 | Cancer Res. | pmid:18829567 |